68 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in May 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
30
Ending by 2030
May 2027
Next term end
42
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2028 · High confidence
Also notable
Ends Apr 2029 · High confidence
Also notable
Ends Nov 2028 · High confidence
Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens
US 9,284,349
Cited by 44 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof
US 8,378,081
Cited by 32 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides
US 8,557,955
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 2 to 30, 2026 · next Dec 2
- 4 fees due Jan 7 to 28, 2027 · next Jan 7
- 1 fee due Feb 25, 2027The maintenance fee for A Method of Inducing an Immune Response by Administering Wdrpuh Epitope Peptides (US 9,115,207) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 4 fees due Mar 1 to 15, 2027 · next Mar 1
- 2 fees due May 10 to 24, 2027 · next May 10
- 3 fees due Sep 3 to 24, 2027 · next Sep 3
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 42 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| NEIL3 Peptides and Vaccines Including the Same | 4 in force | to Jul 2032 |
| Hjurp Peptides and Vaccines Including the Same | 3 in force | to Dec 2031 |
| Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof | 3 in force | to May 2031 |
| FOXM1 Peptide and Medicinal Agent Comprising the Same | 3 in force | to Jan 2031 |
| Melk Epitope Peptides and Vaccines Containing the Same | 3 in force | to Jul 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,053,556 | GLYPICAN-3 (GPC3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-POSITIVE Patients and Pharmaceutical Comprising the Same In force · High confidence | In force | High confidence | |
| US 9,545,437 | Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides In force · Medium confidence | In force | Medium confidence | |
| US 9,067,973 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · Medium confidence | In force | Medium confidence | |
| US 9,284,349 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · High confidence | In force | High confidence | |
| US 8,221,751 | Tumor-Targeting Monoclonal Antibodies to FZD10 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,073,968 | FOXM1 Peptide and Medicinal Agent Comprising the Same In force · High confidence | In force | High confidence | |
| US 9,415,096 | FOXM1 Peptide and Medicinal Agent Comprising the Same In force · High confidence | In force | High confidence | |
| US 8,383,590 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · High confidence | In force | High confidence | |
| US 8,557,955 | Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides In force · High confidence | In force | High confidence | |
| US 8,378,081 | Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 68: 4 patents in force now held by others · 61 patents ended · 3 applications pending · 86 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.